SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months ...

Amid Rough Waters, Regeneron Puts Nearly $2B on the Line For Chinese Obesity Drug Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab. June ...